Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neoplasms, Breast: early-phase trial registry
A small indexed set (10 trials) with no open enrollment listed right now.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · none currently recruiting · #1,724 of 28,707 conditions by registered trial count
Neoplasms, Breast: 10 US clinical trials tracked, none currently recruiting.
Neoplasms, Breast is the subject of 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 3 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is GlaxoSmithKline, running 6 of these trials.
Enrollment posture brief
Registry condition neoplasms-breast
OPEN 0 | RECR 0% | LATE 3 | EARLY 6 | RANK #1724 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Neoplasms, Breast has no open enrollment in this registry pull (10 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neoplasms, Breast on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neoplasms, Breast is recruiting below its size-band peers.
0 of 10 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Neoplasms, Breast research.
GlaxoSmithKline accounts for 6 of 10 trials (60%). 3 distinct sponsors appear on at least one study for this condition label.
-
Most Neoplasms, Breast trials plan to enrol fewer than 100 people.
Median target enrolment is 79 among the 10 trials that report a genuine target (sentinel values excluded). 6 of those (60%) plan for fewer than 100 participants.
-
Neoplasms, Breast research is mostly interventional.
10 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
10 total, page 1 of 1
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
GlaxoSmithKline
NCT04915755
ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D
Novartis Pharmaceuticals
NCT00490139
Paclitaxel With / Without GW572016 (Lapatinib) As First Line Therapy For Women With Advanced Or Metastatic Breast Cancer
GlaxoSmithKline
NCT00075270
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
GlaxoSmithKline
NCT00347919
Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer
GlaxoSmithKline
NCT00089999
Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer
Emory University
NCT01271738
A Dose-escalation Vaccine Trial in HER2-overexpressing Patients With High-risk Breast Cancer
GlaxoSmithKline
NCT00058526
Phase II Lapatinib Plus Nab-Paclitaxel As First And Second Line Therapy In her2+ MBC
Novartis Pharmaceuticals
NCT00709761
Effects Of GW572016 In Combination With Docetaxel (TAXOTERE)
GlaxoSmithKline
NCT00148902
Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.
Novartis Pharmaceuticals
NCT00367471
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 3 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Neoplasms, Breast records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neoplasms, Breast trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neoplasms, Breast page
10 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Neoplasms, Breast trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- GlaxoSmithKline sponsors the most Neoplasms, Breast trials on record, review their full trial history before evaluating a specific study. See GlaxoSmithKline's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neoplasms, Breast condition card totals 10 registered trials; most-linked intervention lapatinib; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.